AIP _ ARA9 Antibody
- Known as:
- AIP _ ARA9 Antibody
- Catalog number:
- AF1040a
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- AIP _ ARA9 Antibody
Related genes to: AIP _ ARA9 Antibody
- Gene:
- AIP NIH gene
- Name:
- aryl hydrocarbon receptor interacting protein
- Previous symbol:
- -
- Synonyms:
- XAP2, ARA9, FKBP16
- Chromosome:
- 11q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-22
- Date modifiied:
- 2019-04-23
Related products to: AIP _ ARA9 Antibody
Related articles to: AIP _ ARA9 Antibody
- Autoimmune pancreatitis (AIP) is an uncommon, immune-mediated form of chronic pancreatitis characterized by lymphoplasmacytic infiltration, fibrosis, and frequently elevated serum IgG4 levels. Clinically and radiologically, AIP often mimics pancreatic ductal adenocarcinoma, posing a substantial diagnostic challenge that risks unnecessary surgical interventions. This article presents the case of a 53-year-old female patient with epigastric pain, obstructive jaundice, and a pancreatic head mass initially suggestive of malignancy. Detailed imaging (CT, MRI, MRCP), serological evaluation showing elevated IgG4, and a favorable response to corticosteroid therapy confirmed the diagnosis of type 1 AIP. The case underscores the importance of accurately differentiating AIP from pancreatic malignancies by integrating clinical data, imaging features-particularly the absence of significant double-duct dilatation characteristic of pancreatic cancer-the presence of renal lesions, which represent an unusual metastatic site in pancreatic malignancies, serological markers, histopathological findings, and steroid responsiveness. Early diagnosis is crucial to avoid unwarranted surgery, initiate appropriate immunosuppressive treatment, and ensure favorable long-term outcomes. This report contributes to the growing body of evidence highlighting AIP's diagnostic complexity and underscores the necessity for a multidisciplinary approach in its management. - Source: PubMed
Publication date: 2026/05/09
Diani AbdelwahedBenzalim MariamBouroumane Mohammed RidaAlj Soumaya - Atherogenic index of plasma (AIP) has emerged as a novel marker of atherosclerosis and a predictor of outcomes in patients with coronary artery disease. However, the prognostic significance of AIP in a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) remains unclear. This prospective cohort study included 1179 patients with MINOCA who were stratified by the tertile levels of AIP defined as base 10 logarithm of the ratio of fasting triglyceride to high-density lipoprotein cholesterol. The primary endpoint was major adverse cardiovascular events (MACE) including all-cause death, reinfarction, stroke, revascularization and hospitalization for unstable angina or heart failure. Over the median follow-up of 41.7 months, patients with higher AIP tertiles had more cardiometabolic risk factors and a significantly higher incidence of MACE (9.9%, 14.3%, 18.6%; p = 0.002). Elevated AIP was associated with an increased risk of MACE even after multivariable adjustment [tertile 1 of AIP as reference; tertile 2: hazard ratio (HR) 1.50, 95% confidence interval (CI): 1.03-2.32, p = 0.036; tertile 3: HR 1.78, 95% CI: 1.21-2.63, p = 0.003]. AIP as a continuous marker remained a robust risk factor in all patients and across subgroup analyses. A near-linear relationship was observed between AIP levels and the risk of MACE following MINOCA. Moreover, AIP showed a moderate ability to predict MACE with an area under the curve of 0.67. Higher AIP levels were independently associated with poorer outcomes after MINOCA. These data indicate the role of atherogenic dyslipidemia in MINOCA pathogenesis and support the utility of AIP for risk stratification in this population. - Source: PubMed
Publication date: 2026/05/21
Gao SideHuang SizhuangLiu XinmingYu MengyueZhao Lin - The atherogenic index of plasma (AIP), calculated as log(triglycerides/high-density lipoprotein cholesterol), is a novel marker of atherogenic risk, but its association with cardiovascular disease (CVD) and mortality in early adulthood remains unclear. - Source: PubMed
Publication date: 2026/05/18
He MianwangYin NanaWang ChiFeng ZekunWu ShoulingXue Hao - Quorum sensing (QS) enables bacteria to coordinate collective behaviors by secreting and sensing diffusible signals. Understanding QS at single-cell resolution is essential because population-level measurements often obscure regulatory heterogeneity. In Staphylococcus aureus, the accessory gene regulator (agr) system is a major QS-controlled virulence regulator activated by autoinducing peptides (AIPs). Four agr-types exist, each defined by distinct AIPs and capable of cross-inhibition, yet their activation dynamics and interaction hierarchies remain poorly understood. Using microfluidics, time-lapse microscopy, and deep-learning-based image analysis, we quantified agr-activation in congenic and native agr-type strains. Agr-types differed in sensitivity to their homologous AIPs: agr-III was largely unresponsive, whereas agr-IV was highly sensitive with elevated basal activation. Agr-activation distribution was frequently bimodal (simultaneous existence of agr-ON and agr-OFF cells), driven by subpopulations that never activated or switched to agr-OFF despite constant stimulation. Combining homologous and heterologous AIPs, AIP‑IV suppressed pre‑activated agr-I, while AIP-I had no inhibitory effect on agr‑IV, indicating asymmetric cross‑inhibition. In spatially segregated cocultures, diffusional crosstalk resulted in four reproducible agr-interaction regimes, stable-dominance, stable-, delayed-, or unstable-dual-activation, determined by agr-type pairing and influenced by genetic background. Our approach links single-cell signaling to population outcomes and uncovers agr-type-specific asymmetries with potential consequences for strain competition and virulence. - Source: PubMed
Publication date: 2026/05/20
Bär JulianPivard MarianeCharlton Samuel G VKempchinsky Andrew GGómez-Mejia AlejandroUgolini Giovanni StefanoMairpady Shambat SrikanthSecchi EleonoraZinkernagel Annelies S - Preeclampsia represents an unmasking of underlying vascular and metabolic vulnerability during the physiologic stress of pregnancy. Current first-trimester screening relies heavily on body mass index which incompletely captures qualitative metabolic dysfunction, particularly in non-obese women. In this narrative perspective, we examine the atherogenic index of plasma (AIP; log[TG/HDL-C]), which reflects triglyceride-rich lipoprotein burden and has emerged as a marker of lipid-driven vascular stress independent of adiposity. This article does not follow systematic review methodology (e.g., PRISMA) and is intended to provide a conceptual synthesis rather than an exhaustive review. Emerging obstetric evidence suggests that first-trimester AIP (≤14 weeks) is associated with an increased risk of subsequent preeclampsia, with uric acid (UA) potentially amplifying this relationship through redox-dependent mechanisms. We propose that elevated AIP and UA define an early, detectable oxidative dyslipidemia phenotype characterized by the convergence of lipotoxic and oxidative pathways, leading to endothelial dysfunction, nitric oxide (NO) depletion, platelet activation, and impaired placental perfusion. We further delineate druggable mechanistic nodes within this axis and outline a precision pharmacology framework for biomarker-enriched prevention trials. These nodes include cyclooxygenase-1 (COX-1)-mediated platelet activation (targeted by low-dose aspirin), NO pathway dysregulation (amenable to NO-supportive strategies), and xanthine oxidase-driven oxidative amplification (a potential target of redox-modulating agents). By explicitly linking early metabolic biomarkers to defined vascular pathways, this framework reframes first-trimester screening as a platform for mechanism-guided pharmacologic investigation rather than risk categorization alone. Before clinical integration, essential steps include independent validation across diverse populations, establishment of pregnancy-specific thresholds, demonstration of incremental predictive value beyond existing screening algorithms, and evidence that biomarker-guided strategies improve maternal and perinatal outcomes. Overall, these observations should be considered hypothesis-generating and require further validation before AIP-based assessment can support biologically informed, phenotype-guided prevention strategies within obstetric pharmacology. - Source: PubMed
Publication date: 2026/05/04
Nájera-Segura Nahui SamantaHernández-Huerta María TeresaPérez-Campos EduardoJarquín González Efrén EmmanuelMartínez-Vargas AdriánPérez-Campos Mayoral LauraReyna González WendyRoldán Trejo Ulises JesúsPérez Rodríguez SerafinaBulluck HeerajnarainMartínez Ruíz HéctorCabrera-Fuentes Hector Alejandro